glutamine/inflammation

FIELD OF THE INVENTION The present invention is a method of using luminal glutamine in the prevention of bacterial translocation and Neonatal Necrotizing Enterocolitis (NEC) in vivo. The same treatment is useful to also protect intestinal cells against injuries caused by other infectious agents,

FIELD OF THE INVENTION This invention relates to a nutritional composition for providing glutamine to a human or animal. The invention also relates to a method for providing glutamine to a human or animal and to a method for the treatment of humans and animals requiring supplemental

FIELD OF THE INVENTION This invention concerns a new family of peptide molecules having the capacity especially of stimulating the expression of the cytokines of inflammation and promoting regeneration of tissues. The invention, thus, also pertains to pharmaceutical compositions containing at least

The present invention relates to a class of compounds useful in the diagnosis of sites of venous and arterial thrombosis, embolism or infection, pharmaceutical formulations containing them, their use in the diagnosis of disease and methods for their preparation. Prior approaches to thrombus imaging

TECHNICAL FIELD The present invention relates to an agent for treating or preventing an inflammatory bowel disease, comprising a particular amino acid(s). The present invention also relates to an agent for inhibiting TNF production, comprising a particular amino acid(s). BACKGROUND ART An

BACKGROUND OF THE INVENTION Ulcerative colitis (UC) is an inflammatory bowel disease characterized by recurrent bouts of rectal bleeding and bloody diarrhea. The initial inflammatory reaction begins in the rectal mucosa in over 95% of cases and may extend in a contiguous fashion to involve the whole

BACKGROUND OF THE INVENTION Ulcerative colitis (UC) is an inflammatory bowel disease characterized by recurrent bouts of rectal bleeding and bloody diarrhea. The initial inflammatory reaction begins in the rectal mucosa in over 95% of cases and may extend in a contiguous fashion to involve the whole

BACKGROUND OF THE INVENTION Maintaining the well being of the GI tract of a mammal is a very desirable goal. Particularly annoying are inflammatory conditions of the GI tract. Some of the signs of inflammation of the GI tract include acute or chronic diarrhea, soft stools, blood in stool, vomiting,

The invention is related to nutritional, pharmaceutical or dietetic preparations that comprise ribose or folic acid or functional analogs thereof and the use of these compositions in the prevention or treatment of specific diseases that are related to disorders or insufficiencies of total nucleotide

The invention is related to nutritional, pharmaceutical, or dietetic preparations that comprise ribose or folic acid or functional analogs thereof and the use of these compositions in the prevention or treatment of specific diseases that are related to disorders or insufficient of total nucleotide

The invention relates to a method of treating disorders of the animal or human body which require increasing blood flow to intestinal organs as well as to a method of treating disorders which can be treated by administering arginine. The present invention relates in particular to the use of

FIELD OF THE INVENTION The invention relates to peptides having biological and therapeutic activity. Particularly, the invention relates to tetrapeptides that inhibit inflammatory processes in skin. Such tetrapeptides exert this effect, in part, by reducing the amount of interleukin (IL)-6 and

CROSS-REFERENCE TO RELATED APPLICATIONS This Non-provisional application claims priority under 35 U.S.C. .sctn.119(a) on Patent Application No. 100138960 filed in Taiwan, Republic of China Oct. 26, 2011, the entire contents of which are hereby incorporated by reference. FIELD OF THE INVENTION This

FIELD OF THE INVENTION The invention relates to compositions for topical application to human skin, hair, or nails, which compositions contain transglutaminase and a beneficial active ingredient containing, or so modified as to contain, an alkylamine group. BACKGROUND OF THE